Sepsis Diagnostic Market
The Global Sepsis Diagnostics Market Size reached USD 0.88 billion in 2026 and is expected to reach USD 1.4 billion by 2031, growing at a CAGR of 9.5% during the forecast period 2026-2031.
Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.
Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.
Sepsis Diagnostic Market Scope
| Metrics | Details |
| CAGR | 9.5% |
| Market Size Available for Years | 2026-2031 |
| Estimation Forecast Period | 2026-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product, Technology, Diagnostic Method, Pathogen, End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
Sepsis DiagnosticMarket Dynamics: Drivers & Restraints
The growing burden of infectious diseases
If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.
As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.
In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.
Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.
High Cost of Diagnostic Tools
Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.
Key Takeaways
- The Global Digital X-ray Market is stated at USD 0.88 billion in 2026 and is expected to reach USD 1.4 billion by 2031, advancing at a CAGR of 9.5% during 2026–2031.
- Portable digital X-ray systems are commercially important because they allow bedside imaging in ICUs, emergency departments and other settings where moving patients to a fixed radiography room is difficult. DataM identifies portable systems as the leading portability segment.
- Flat-panel detectors, rapid image acquisition and digital image processing are replacing film-dependent workflows. DR systems can deliver images directly from the detector, reducing cassette handling and supporting faster clinical review.
- AI-assisted positioning and workflow automation are moving from optional software features toward practical radiography tools. Recent systems use cameras, positioning guidance and automated examination functions to reduce positioning errors and repeat exposures.
- PACS and enterprise imaging connectivity are increasingly important because digital X-ray images can be transferred, stored and accessed electronically across clinical workflows. Fujifilm's recent radiography portfolio, for example, combines DR equipment with healthcare IT and interoperability capabilities.
- The main adoption barrier remains the total cost of ownership, including detectors, installation, service, software upgrades and staff training. Detector replacement and maintenance can materially increase the long-term cost of a DR installation.
- North America, particularly the United States, holds an important position in the DataM Intelligence assessment, supported by established imaging manufacturers and healthcare investment, while Asia-Pacific is identified as the fastest-growing regional market.
Sepsis Diagnostic Segment Analysis
The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.
Blood Culture Media segment is expected to dominate the market growth
Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.
While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the sepsis diagnostic market share
North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.
Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.
Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.
Market Segmentation
By Product
- Instruments
- Software
- Blood Culture Media
- Assays & Reagents
- Others
By Technology
- Flow Cytometry
- Microbiology
- Biomarkers
- Molecular Diagnostics
- Microfluidics
- Others
By Pathogen
- Automated Diagnostics
- Conventional Diagnostics
By Diagnostic Method
- Fungal Sepsis
- Bacterial Sepsis
- Gram-Positive Bacterial Sepsis
- Gram-Negative Bacterial Sepsis
- Other Pathogens
By End-User
- Hospitals
- Pathology & Reference Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMérieux SA, and Immunexpress Inc. among others.
Key Developments
FUJIFILM Introduces FDR Smart X Essential — January 30, 2026: FUJIFILM India introduced the FDR Smart X Essential digital radiography system, expanding its DR portfolio for radiology departments handling growing imaging workloads.- Shimadzu Releases RADspeed Pro XF — March 30, 2026: Shimadzu released the RADspeed Pro XF floor-mounted radiography system in overseas markets excluding the U.S. Its automatic tracking function aligns the X-ray tube and detector, reducing manual positioning.
- Varex Imaging Receives FDA Clearance for Nexus DRF — May 29, 2026: The U.S. FDA granted 510(k) clearance to Varex Imaging's Nexus DRF Digital X-ray Imaging System, supporting its regulatory entry into the U.S. diagnostic imaging market.
- FDA Updates Recognized X-ray Device Standards — May 25, 2026: The FDA updated recognized consensus standards relevant to stationary X-ray systems, flat-panel digital imagers and mobile X-ray systems, supporting manufacturers in regulatory submissions and conformity assessment.
- Japan Advances Medical DX Program — April 14, 2026: Japan's MHLW continued implementation of its Medical DX program, including work on standardized electronic medical records that supports greater interoperability across digitally connected healthcare systems.
- Japan Updates Medical Reimbursement Digitalization Measures — June 19, 2026: MHLW updated its Medical DX initiatives concerning digitalization of medical reimbursement, contributing to Japan's wider healthcare information-system modernization.
- Japan Publishes Medical DX Dashboard — July 7, 2026: MHLW published a Medical DX dashboard to monitor progress in healthcare digitalization, providing further support for connected electronic healthcare and diagnostic-information infrastructure.
Why Purchase the Report?
- To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 216 pages.
